| Literature DB >> 23536793 |
Marcel Adler1, Eduard Murani, Ronald Brunner, Siriluck Ponsuksili, Klaus Wimmers.
Abstract
The aim of the present study was to characterize in vivo genome-wide transcriptional responses to immune stimulation in order to get insight into the resulting changes of allocation of resources. Vaccination with tetanus toxoid was used as a model for a mixed Th1 and Th2 immune response in pig. Expression profiles of PBMCs (peripheral blood mononuclear cells) before and at 12 time points over a period of four weeks after initial and booster vaccination at day 14 were studied by use of Affymetrix GeneChip microarrays and Ingenuity Pathway Analysis (IPA). The transcriptome data in total comprised more than 5000 genes with different transcript abundances (DE-genes). Within the single time stages the numbers of DE-genes were between several hundred and more than 1000. Ingenuity Pathway Analysis mainly revealed canonical pathways of cellular immune response and cytokine signaling as well as a broad range of processes in cellular and organismal growth, proliferation and development, cell signaling, biosynthesis and metabolism. Significant changes in the expression profiles of PBMCs already occurred very early after immune stimulation. At two hours after the first vaccination 679 DE-genes corresponding to 110 canonical pathways of cytokine signaling, cellular immune response and other multiple cellular functions were found. Immune competence and global disease resistance are heritable but difficult to measure and to address by breeding. Besides QTL mapping of immune traits gene expression profiling facilitates the detection of functional gene networks and thus functional candidate genes.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23536793 PMCID: PMC3607572 DOI: 10.1371/journal.pone.0058306
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Experimental Design.
Animals were vaccinated twice with TT. Directly before (0), as well as 2, 4, 8, 24 and 75 hours after each vaccination blood samples were collected. A final blood sample was taken at day 28. Pairwise comparisons of the reference time 0 hours against each following sampling time point were set up for the identification of DE-genes. * reference time point.
Primer sequences used for quantitative real-time PCR.
| Gene | Probe set ID | Outer primer sequence 5′-3′ | Inner primer sequence 5′-3′ |
| KRAS | Ssc.29092.1.A1_at | – | For TTCGTGTTCCCTCAATGTTTC Rev |
| RPS6KB1 | Ssc.22127.1.S1_at | For TGATGAATGTCTTCCACAGTGA Rev | For CCTGCCTTAAAGAGCATTTCC Rev |
| CD8A | Ssc.23489.1.S1_at | For CTGAATCCTGGAAAGTGAACAA Rev | For CACGACCTCTAAAGGAAATCCA Rev |
| CALR | Ssc.3106.1.S1_at | For GGAGTTTGGCAACGAGACAT Rev | For AGGCCAAGGATGAGCTGTAG Rev |
| STAT1 | Ssc.6025.2.A1_at | For CGGGGCATAAAAGTTGTGTT Rev | For GGCTTTATGCTGCTGGCTAC Rev |
| HPRT1 | Ssc.4158.1.S1_at | – | For GTGATAGATCCATTCCTATGACTGTAGA Rev |
| PPIA | Ssc.8046.1.A1_at | For AGCACTGGGGAGAAAGGATT Rev | For GATTTATGTGCCAGGGTGGT Rev |
reference genes used for normalization.
Number, direction and q-values [34] of DE-genes (p<0.05) over the time points of blood sampling after vaccination.
| Time after 1st vaccination | 2 h | 4 h | 8 h | 24 h | 75 h | d 14 |
| Number of DE-genes | 679 | 1196 | 1104 | 773 | 549 | 642 |
| increased transcript abundance | 417 | 1063 | 889 | 233 | 118 | 207 |
| decreased transcript abundance | 262 | 133 | 215 | 540 | 431 | 435 |
| q-value (at p = 0.05) | 0.24 | 0.08 | 0.08 | 0.22 | 0.36 | 0.21 |
|
|
|
|
|
|
|
|
| Number of DE-genes | 485 | 358 | 824 | 942 | 1121 | 527 |
| increased transcript abundance | 301 | 187 | 406 | 557 | 259 | 408 |
| decreased transcript abundance | 184 | 171 | 418 | 385 | 862 | 119 |
| q-value (at p = 0.05) | 0.49 | 0.59 | 0.24 | 0.15 | 0.09 | 0.32 |
Top 20 canonical pathways within the first 24 h of immune response after the first vaccination.
| Ingenuity Canonical Pathway | Pathway Category | −log p at 2 h | −log p at 4 h | −log p at 8 h | −log p at 24 h |
| Fcγ Receptor-mediated Phagocytosis inMacrophages and Monocytes | 1 | 6.79 | 2.25 | 2.37 | 6 |
| CD28 Signaling in T Helper Cells | 1 | 4.92 | n.s. | 1.68 | 5.63 |
| CTLA4 Signaling in Cytotoxic T Lymphocytes | 1 | 3.64 | n.s. | n.s. | 6.06 |
| T Cell Receptor Signaling | 1 | 2.2 | n.s. | 3.22 | 5.79 |
| Regulation of IL-2 Expression in Activated andAnergic T Lymphocytes | 1; 2 | 1.48 | n.s. | 4.13 | 2.31 |
| Clathrin-mediated Endocytosis Signaling | 1; 3; 9 | 4.15 | 2.66 | n.s. | 4.63 |
| ILK Signaling | 4 | 4.69 | 2.03 | n.s. | 1.59 |
| FAK Signaling | 4 | 3.83 | 1.58 | 1.68 | 4 |
| VEGF Signaling | 4; 10 | 3.11 | 2.98 | 2.6 | 4.74 |
| IGF-1 Signaling | 4; 10 | 1.61 | 3.5 | 2.63 | 3.54 |
| Integrin Signaling | 4; 5; 7 | 6.2 | 2.74 | 2.94 | 4.08 |
| Protein Ubiquitination Pathway | 5 | 1.45 | 3.7 | 5.69 | n.s. |
| ERK/MAPK Signaling | 5 | 3.01 | 2.05 | 4.26 | 5.09 |
| Glucocorticoid Receptor Signaling | 5 | 2.59 | 2.95 | 4.76 | 3.65 |
| Estrogen Receptor Signaling | 6 | n.s. | 3.82 | 4.02 | n.s. |
| Aldosterone Signaling in Epithelial Cells | 6; 12 | 2.6 | 2.47 | 3.06 | 2.12 |
| NRF2-mediated Oxidative Stress Response | 8; 13 | 2.11 | 2.14 | 5.93 | 1.66 |
| Actin Cytoskeleton Signaling | 9 | 5.15 | 3.11 | 4.62 | 4.81 |
| Regulation of Actin-based Motility by Rho | 11 | 3.94 | 3.68 | 1.36 | 1.62 |
| Ephrin Receptor Signaling | 9 | 2.71 | n.s. | n.s. | 5.45 |
1 Cellular Immune Response.
2 Cytokine Signaling.
3 Pathogen-Influenced Signaling.
4 Cellular Growth, Proliferation and Development.
5 Intracellular and Second Messenger Signaling.
6 Nuclear Receptor Signaling.
7 Cell Cycle Regulation.
8 Cellular Stress and Injury.
9 Organismal Growth and Development.
10 Growth Factor Signaling.
11 Neurotransmitters and Other Nervous System Signaling.
12 Cardiovascular Signaling.
13 Ingenuity Toxicity List Pathways.
n.s. not significant.
Top 20 canonical pathways within 24 h of immune response after the second vaccination on day 14.
| Ingenuity Canonical Pathway | Pathway Category | −log p at 2 h | −log p at 4 h | −log p at 8 h | −log p at 24 h |
| Fcγ Receptor-mediated Phagocytosis inMacrophages and Monocytes | 1 | n.s. | n.s. | 3.77 | 3.36 |
| fMLP Signaling in Neutrophils | 1; 3 | n.s. | n.s. | 3.8 | 2.82 |
| Clathrin-mediated Endocytosis Signaling | 1; 4; 10 | 1.69 | n.s. | 4.88 | 2.78 |
| Tumoricidal Function of Hepatic Natural Killer Cells | 1; 6 | 1.64 | 1.54 | n.s. | n.s. |
| B Cell Receptor Signaling | 2 | n.s. | n.s. | 3.18 | 3.23 |
| Role of MAPK Signaling in the Pathogenesis of Influenza | 4; 5 | 1.62 | 1.48 | 1.84 | 1.63 |
| Atherosclerosis Signaling | 5; 13 | n.s. | 2.39 | n.s. | n.s. |
| SAPK/JNK Signaling | 6 | n.s. | n.s. | 5.84 | 2.75 |
| Integrin Signaling | 7; 8; 9 | 2.46 | 2.15 | 3.69 | 3.59 |
| ILK Signaling | 7 | n.s. | n.s. | 5.17 | 1.84 |
| VEGF Signaling | 7; 11 | n.s. | n.s. | 4.04 | 4.27 |
| Protein Kinase A Signaling | 8 | n.s. | 3.74 | 4.31 | n.s. |
| Glucocorticoid Receptor Signaling | 8 | n.s. | n.s. | 2.37 | 3.79 |
| Insulin Receptor Signaling | 8 | 2.05 | n.s. | 1.65 | 1.77 |
| Actin Cytoskeleton Signaling | 10 | 2.3 | n.s. | 5.37 | 5.16 |
| Ephrin Receptor Signaling | 10 | 2.15 | 1.35 | 1.66 | n.s. |
| Regulation of Actin-based Motility by Rho | 12 | 1.31 | n.s. | 2.87 | 3.13 |
| Inhibition of Angiogenesis by TSP1 | 13 | 2.36 | n.s. | 3.21 | n.s. |
| Aminosugars Metabolism | 14 | n.s. | 2.9 | n.s. | n.s. |
| N-Glycan Degradation | 15 | n.s. | 2.48 | n.s. | n.s. |
1 Cellular Immune Response.
2 Humoral Immune Response.
3 Cytokine Signaling.
4 Pathogen-Influenced Signaling.
5 Disease-Specific Pathways.
6 Apoptosis.
7 Cellular Growth, Proliferation and Development.
8 Intracellular and Second Messenger Signaling.
9 Cell Cycle Regulation.
10 Organismal Growth and Development.
11 Growth Factor Signaling.
12 Neurotransmitters and Other Nervous System Signaling.
13 Cardiovascular Signaling.
14 Carbohydrate Metabolism.
15 Glycan Biosynthesis and Metabolism.
n.s. not significant.
Figure 2Most affected biofunctions within 24 hours after the first and after the second vaccination.
Segments of the respective bars for the first and the second vaccination represent the relative frequencies of IPA biofunctional categories superior to canonical pathways that are most significant at 2 h, 4 h, 8 h and 24 h after immunization.
Correlation between microarray gene expression and results of quantitative real-time PCR for selected genes.
| Gene | Spearman’s rho | p-value | Number of involved canonical pathways |
| KRAS | 0.58 | <0.01 | 92 |
| RPS6KB1 | 0.58 | <0.01 | 20 |
| CD8A | 0.35 | 0.07 | 3 |
| CALR | 0.36 | 0.06 | 4 |
| STAT1 | 0.42 | 0.04 | 26 |